OTCPK:HESG

Stock Analysis Report

Executive Summary

Health Sciences Group Inc., through its subsidiaries, provides various products used in nutritional supplements and functional foods and beverages in the United States.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Health Sciences Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: HESG's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

9900.0%

HESG

0.6%

US Consumer Retailing

-1.1%

US Market


1 Year Return

900.0%

HESG

17.6%

US Consumer Retailing

17.8%

US Market

Return vs Industry: HESG underperformed the US Consumer Retailing industry which returned 17.5% over the past year.

Return vs Market: HESG underperformed the US Market which returned 17.9% over the past year.


Shareholder returns

HESGIndustryMarket
7 Day9900.0%0.6%-1.1%
30 Day9900.0%2.5%1.5%
90 Day900.0%0.3%6.6%
1 Year900.0%900.0%19.8%17.6%20.2%17.8%
3 Year0%0%48.6%39.0%47.5%38.1%
5 Year0%0%48.3%32.9%71.2%52.4%

Price Volatility Vs. Market

How volatile is Health Sciences Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Health Sciences Group undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Health Sciences Group is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Health Sciences Group has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of HESG’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Health Sciences Group regulatory filings here.
  • Explore potentially undervalued companies in the Consumer Retailing industry.

Future Growth

How is Health Sciences Group forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

5.1%

Forecasted Consumer Retailing industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Health Sciences Group has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Health Sciences Group performed over the past 5 years?

7.7%

Historical Consumer Retailing annual earnings growth


In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Health Sciences Group has not provided sufficient past data to assess its track record.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.


Next Steps

Financial Health

How is Health Sciences Group's financial position?


In this section we usually analyse Health Sciences Group's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Health Sciences Group has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.


Next Steps

  • Take a look at our analysis of HESG’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • Investors tend to look at the financial health of a company this size in order to assess the sustainability of its current operations. While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website.
  • Financial health is measured at one point in time, so the latest financial report is the best representation of the company’s current financial status. Check when Health Sciences Group's financial data was last updated here.
  • Explore more healthy companies in the Consumer Retailing industry.

Dividend

What is Health Sciences Group's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate HESG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate HESG's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HESG's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HESG's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of HESG's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

16.1yrs

Average management tenure


CEO

Thomas Gaffney 0

Mr. Thomas Gaffney serves as President and Chief Executive Officer at Health Sciences Group, Inc. 


Leadership Team

NamePositionTenureCompensationOwnership
Thomas Gaffney
Chief Executive Officer and President0yrsno datano data
Raymond Signore
Director of Sales & Marketing16.3yrsno datano data
Fred Aserati
Vice President of Business Development10.3yrsno datano data
Jeffrey Klar
Chief Operating Officer of Quality Botanical Ingredients (QBI) Division16.2yrsno datano data
Allan Himmelstein
President of Quality Botanical Ingredients16yrsno datano data

16.1yrs

Average Tenure

Experienced Management: HESG's management team is seasoned and experienced (16.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dean Blechman
Member of Advisory Board14.6yrsno datano data
Joseph Hines
Member of the Advisory Board16.9yrsno datano data
William Walker
Outside Director16.8yrsno datano data
Carlon Colker
Chairman of Scientific Advisory Board14.5yrsno datano data
Anthony DeBella
Director11yrsno datano data

14.6yrs

Average Tenure

72yo

Average Age

Experienced Board: HESG's board of directors are seasoned and experienced ( 14.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Insufficient data to determine if shareholders have been diluted in the past year.


Top Shareholders

Company Information

Health Sciences Group, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Health Sciences Group, Inc.
  • Ticker: HESG
  • Exchange: OTCPK
  • Founded: 1996
  • Industry: Drug Retail
  • Sector: Consumer Retailing
  • Market Cap: US$2.051m
  • Shares outstanding: 20.51b
  • Website: https://null

Location

  • Health Sciences Group, Inc.
  • 2549 Eastbluff Drive
  • Suite 216
  • Newport Beach
  • California
  • 92660
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HESGOTCPK (Pink Sheets LLC)YesCommon StockUSUSDAug 2001

Biography

Health Sciences Group Inc., through its subsidiaries, provides various products used in nutritional supplements and functional foods and beverages in the United States. It primarily offers Shugr, a zero-calorie sugar substitute that tastes and bakes like cane sugar; and Sequesterol Advance Cardio Formula, a proprietary blend of clinically studied ingredients for the maintenance of cardiovascular health and a free-flowing circulatory system. The company also offers Aplevia, an antioxidant derived from apple peels; and Edible Sponges, an open-cell hydrocolloid product. It sells its products primarily through mass market retailers, such as mass merchandisers, drug stores, supermarkets, and discount stores, as well as through healthcare professionals and practitioners, and other media. Health Sciences Group was founded in 1996 as Centurion Properties Development Corporation and changed its name to iGoHealthy.com in 2000. It changed its name to Health Sciences Group, Inc. in 2001. The company is based in Newport Beach, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 01:40
End of Day Share Price2020/02/21 00:00
Earnings2006/09/30
Annual Earnings2005/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.